Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
about
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceEffects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceBreast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexesSafety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model.Selective estrogen receptor modulators: tissue specificity and clinical utility.A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?Bazedoxifene: literature data and clinical evidenceSelective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse modelThe selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosisThe Tissue-Selective Estrogen Complex: A Review of Current EvidenceCost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in SpainProfile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fractureThe tissue selective estrogen complex: a promising new menopausal therapyEndometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.Conjugated estrogens and bazedoxifeneBazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.Current, new and future treatments of osteoporosis.Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.Individualizing osteoporosis therapy.Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.Selective estrogen receptor modulators in clinical practice: a safety overview.Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer.Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene.The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause.Recent Developments in Pharmacotherapy for Vasomotor Symptoms
P2860
Q26830744-F29FEB63-0270-4BA1-BC1C-D4579908F777Q30380010-95986D75-5E6E-46F8-81F2-806177A38315Q30409045-7008C85F-364C-41E6-9839-755D44A83C34Q33613016-208DDDA0-B108-410D-A47C-FBFA0970C913Q33888331-32FE9B4B-9121-48E5-BB3C-2EB41FAF0958Q34134828-6B7A1617-7D41-45A8-AACA-99166D7E57E6Q34161156-3654CBE6-6193-4D80-9E37-FC796629F0D1Q34213748-DE2F634D-9A49-4F81-98A1-E18EE0EAFD8CQ34490225-CB9383DB-1593-4E73-9428-212A97553CA6Q35092609-97C8FE33-BE1B-42B7-A480-A87A6C0E2C7BQ35092811-E6F11F81-109C-497C-BE46-2ACBE276F853Q35110859-A7FD771D-2CBF-46BC-8835-FEDA2C2932BCQ35275278-F99DEF65-4A8F-48C7-BC83-64B918158589Q36059535-04DD1B67-2396-4F62-8F0B-1FB53FAF5EC2Q36942968-EEB68D45-95E5-4EAE-A18A-813D9B3AF1FBQ37006842-CF8AE997-F82B-42C6-BC34-73DC64652926Q37048294-C2B64347-98AD-400C-A238-EF14912790B7Q37277298-760AFEF9-303C-4CFA-9D9F-FD7943CE15CFQ37648048-2C28A8B1-9B43-49A4-B9A9-56D8F544A5DEQ37676345-B351F2CB-B25B-4933-9390-91A76C3EDF1BQ37698607-68F2F2E2-EBE2-4348-B488-798E73BFEAB4Q37777053-2F60E972-01B1-4256-9109-CE62E4FFA019Q37950520-C3FA460B-1B87-47A5-809E-C5B08BF584C4Q37973239-7062159F-E104-44B2-83A1-851BE931EF4DQ38102040-DB94F770-7050-410E-831F-82BA41752A29Q38193873-C964A2DD-C949-4366-A804-42ADD5C699C7Q38455538-CEF87D17-3D31-40AB-BAF6-F40DDDD59083Q42133030-818E74E4-1224-4050-B632-10B31A825893Q43803456-222B94B7-614E-494E-B786-EBE55C2927ADQ46417845-8C7EA8B6-B597-43C6-BF6B-D63ABAF41EC8Q46718995-FBFF28B0-C727-410C-8628-0E5755960A59Q48189748-C91721ED-8111-4713-8BB3-861718BF88B7Q56390891-3DD38F2C-FC62-4839-BFC7-984B07767BDA
P2860
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@ast
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@en
type
label
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@ast
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@en
prefLabel
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@ast
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@en
P2093
P1433
P1476
Bazedoxifene effects on the re ...... omen at risk for osteoporosis.
@en
P2093
Amy B Levine
Arkadi A Chines
David F Archer
Ginger D Constantine
JoAnn V Pinkerton
José C Menegoci
Wulf H Utian
P304
P356
10.1097/GME.0B013E3181A816BE
P407
P577
2009-11-01T00:00:00Z